Radiopharm Theranostics Ltd (RADX) Price Prediction & ForecastRADXRadiopharm Theranostics Ltd

Alphio's RADX stock price prediction model matches the current Radiopharm Theranostics Ltd tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $1.04 (-0.63%). The 1-week path is $1.00 (-4.16%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Radiopharm Theranostics Limited (RADX) appears to be a good buy right now due to its recent positive clinical trial results and a significant price target from analysts. The stock is currently priced at $1.04, which is substantially lower than its 52-week high of $16.25, indicating potential for recovery. Additionally, the RSI is at 48.55, suggesting the stock is neither overbought nor oversold, which is favorable for entry. The recent announcement of a pivotal Phase 3 trial for RAD101, which has shown a 93% concordance in detecting brain metastases, adds to the positive outlook. However, the main risk is its current negative P/E ratio of -0.25, indicating that the company is not yet profitable, which could affect long-term performance.

Radiopharm Theranostics Ltd (RADX) last closed at $1.044, gaining +17.44%. These facts feed the 1-day and 1-week RADX price prediction above.